GBDO Collaborators, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, Marczak L, Mokdad AH, Moradi-Lakeh M et al (2017) Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med 377(1):13–27

Article  Google Scholar 

Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

de Azambuja E, McCaskill-Stevens W, Francis P, Quinaux E, Crown JP, Vicente M, Giuliani R, Nordenskjold B, Gutierez J, Andersson M et al (2010) The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02–98 trial. Breast Cancer Res Treat 119(1):145–153

Article  Google Scholar 

Desmedt C, Fornili M, Clatot F, Demicheli R, De Bortoli D, Di Leo A, Viale G, de Azambuja E, Crown J, Francis PA et al (2020) Differential benefit of adjuvant docetaxel-based chemotherapy in patients with early breast cancer according to baseline body mass index. J Clin Oncol 38(25):2883–2891

Article  CAS  Google Scholar 

Sparreboom A, Wolff AC, Mathijssen RH, Chatelut E, Rowinsky EK, Verweij J, Baker SD (2007) Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 25(30):4707–4713

Article  CAS  Google Scholar 

Francis P, Crown J, Di Leo A, Buyse M, Balil A, Andersson M, Nordenskjold B, Lang I, Jakesz R, Vorobiof D et al (2008) Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02–98 randomized trial. J Natl Cancer Inst 100(2):121–133

Article  CAS  Google Scholar 

Sonnenblick A, Francis PA, Azim HA Jr, de Azambuja E, Nordenskjold B, Gutierez J, Quinaux E, Mastropasqua MG, Ameye L, Anderson M et al (2015) Final 10-year results of the Breast International Group 2–98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. Eur J Cancer 51(12):1481–1489

Article  CAS  Google Scholar 

Rowinsky EK, Donehower RC (1995) Paclitaxel (taxol). N Engl J Med 332(15):1004–1014

Article  CAS  Google Scholar 

Gota V, Nookala M, Bonda A, Karanam A, Shriyan B, Kembhavi Y, Gurjar M, Patil A, Singh A, Goyal N et al (2021) Effect of body mass index on pharmacokinetics of paclitaxel in patients with early breast cancer. Cancer Med 10(9):3068–3076

Article  CAS  Google Scholar 

Eisen ASA, Yeung L, Iyer R, Trudeau M (2013) Abstract P3-12-11: provincial variation in utilization of adjuvant chemotherapy regimens in early stage breast cancer: data from the cancer care Ontario new drug funding program (NDFP). In: SABCS: 2013; United States: Cancer Research, pp 3–12

Moon HG, Han W, Noh DY (2009) Underweight and breast cancer recurrence and death: a report from the Korean Breast Cancer Society. J Clin Oncol 27(35):5899–5905

Article  Google Scholar 

Brygger L, Herrstedt J (2014) Academy of geriatric cancer R: 5-hydroxytryptamine3 receptor antagonists and cardiac side effects. Expert Opin Drug Saf 13(10):1407–1422

Article  CAS  Google Scholar 

Fleet JL, Shariff SZ, Bailey DG, Gandhi S, Juurlink DN, Nash DM, Mamdani M, Gomes T, Patel AM, Garg AX (2013) Comparing two types of macrolide antibiotics for the purpose of assessing population-based drug interactions. BMJ Open 3(7):e002857

Article  Google Scholar 

Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA (2003) Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 289(13):1652–1658

Article  CAS  Google Scholar 

Burnell M, Levine MN, Chapman JA, Bramwell V, Gelmon K, Walley B, Vandenberg T, Chalchal H, Albain KS, Perez EA et al (2010) Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol 28(1):77–82

Article  CAS  Google Scholar 

Pajares B, Pollan M, Martin M, Mackey JR, Lluch A, Gavila J, Vogel C, Ruiz-Borrego M, Calvo L, Pienkowski T et al (2013) Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. Breast Cancer Res 15(6):R105

Article  Google Scholar 

Ladoire S, Dalban C, Roche H, Spielmann M, Fumoleau P, Levy C, Martin AL, Ecarnot F, Bonnetain F, Ghiringhelli F (2014) Effect of obesity on disease-free and overall survival in node-positive breast cancer patients in a large French population: a pooled analysis of two randomised trials. Eur J Cancer 50(3):506–516

Article  CAS  Google Scholar 

Chen N, Li Y, Ye Y, Palmisano M, Chopra R, Zhou S (2014) Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel. J Clin Pharmacol 54(10):1097–1107

Article  CAS  Google Scholar 

Barrett SV, Paul J, Hay A, Vasey PA, Kaye SB, Glasspool RM (2008) Scottish Gynaecological Cancer Trials G: does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial. Ann Oncol 19(5):898–902

Article  CAS  Google Scholar 

Di Cosimo S, Porcu L, Agbor-Tarh D, Cinieri S, Franzoi MA, De Santis MC, Saura C, Huober J, Fumagalli D, Izquierdo M et al (2020) Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial. Breast Cancer Res 22(1):115

Article  Google Scholar 

Jiralerspong S, Goodwin PJ (2016) Obesity and breast cancer prognosis: evidence, challenges, and opportunities. J Clin Oncol 34(35):4203–4216

Article  CAS  Google Scholar 

Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K (2016) International Agency for Research on Cancer Handbook Working G: body fatness and cancer-viewpoint of the IARC Working Group. N Engl J Med 375(8):794–798

Article  Google Scholar 

Playdon MC, Bracken MB, Sanft TB, Ligibel JA, Harrigan M, Irwin ML (2015) Weight gain after breast cancer diagnosis and all-cause mortality: systematic review and meta-analysis. J Natl Cancer Inst 107(12):djv275

Article  Google Scholar 

Schmidt P, Cortes J, Dent R, Pusztai L, McArthur H, Kummel S, Bergh J, Denkert C, Park YH, Hui R et al (2022) Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med 386:556–567

Article  Google Scholar